- Home
- RCS vs FHTX Comparison
RCS vs FHTX Comparison
Compare RCS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | FHTX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.0M | 213.8M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RCS | FHTX |
|---|---|---|
| Price | $4.94 | $3.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 160.6K | ★ 405.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $4.84 | $3.27 |
| 52 Week High | $8.00 | $7.61 |
Technical Indicators
Market Signals| Indicator | RCS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 21.71 |
| Support Level | N/A | N/A |
| Resistance Level | $5.67 | $5.27 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 24.29 | 4.50 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.